Author

T. Sanda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. Boersma· 1 shared A. Pichler· 1 shared A. T. Look· 1 shared B. Maurer· 1 shared C. Bock· 1 shared C. Schweicker· 1 shared C. Wagner· 1 shared C. Y. Goh· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Boersma

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ChIP-MS reveals the local chromatin composition by label-free quantitative proteomics

W. K. Yong, G. Rane, N. Zaal Anuar, X. Shao, C. Y. Goh, V. Khanchandani, V. L. S. Kuan, M. Jeitany, P. Koeffler, L.-W. Deng, T. Sanda, D. Kappei

The paper introduces ChIP-MS, a method combining ChIP with label-free quantitative mass spectrometry to analyze local chromatin composition, demonstrating its application at telomeres, with transcription factors, in tissue, and via dCas9-driven enrichment.

bioRxiv · Jan 27, 2023Biochemistry

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology